Basel Medical Group Ltd Files FY2026 Annual Report on Form 20-F
Basel Medical Group Ltd filed its annual report on Form 20-F for the fiscal year ended June 30, 2026, reporting revenue of S$16.4 million (US$12.8 million), a 45.2% increase from S$11.3 million in FY2025. The company completed its acquisition of Bethesda Medical Pte. Ltd. in April 2025 and recognized a full goodwill impairment of S$10.3 million related to the acquisition. Subsequent to year-end, the company completed a registered direct offering raising approximately US$7.98 million in gross proceeds and is defe...
Key takeaways
Revenue increased 45.2% year-over-year to S$16.4 million (US$12.8 million) driven by higher business activity and the Bethesda Medical acquisition.
Loss before tax improved significantly to S$1.2 million (US$0.97 million) from S$11.1 million in FY2025, despite recognizing S$10.3 million goodwill impairment in FY2025.
The company completed the Bethesda Medical acquisition in April 2025, adding six general practice clinics, with full goodwill impairment recognized in FY2025.
A securities class action lawsuit was filed in July 2026 alleging violations of the Securities Act of 1933 in connection with registration statements; management believes the allegations are without merit.
In October 2026, the company completed a registered direct offering of 6,000,000 units at US$1.33 per unit, raising gross proceeds of approximately US$7.98 million.
The company effected a 1-for-12 reverse share split in June 2026 to regain compliance with Nasdaq's minimum bid price requirement.
Trade and other receivables represented 85.3% of current assets at S$10.3 million (US$8.0 million) as of June 30, 2026.
Key metrics
Customer concentration
Disclosure changes
- Securities class action lawsuit
A securities class action lawsuit was filed on July 23, 2026 in the Supreme Court of the State of New York naming the company and other defendants, alleging violations of the Securities Act of 1933 in connection with alleged misstatements in registration statements relating to initial public offerings.
Material litigation exposure; plaintiffs seeking compensatory damages which have not been quantified; management believes allegations are without merit. - Board composition changes
Three new directors (Xinwen Yang, Juan Cao, Frederick Shieh Ming Hong) appointed in September 2026; three directors (Keng Leong Fung Raymond, and two others) resigned in September 2026. Total board consists of six directors including four independent directors.
Changes in board composition may affect corporate governance and strategic direction. - Executive leadership changes
Dr. Darren Chhoa appointed as Group CEO in June 2024; Alton Neo appointed as Interim CFO in June 2026; Darren Tan Boon Chye appointed as Chief Commercial Officer in August 2025; Dr. Jeffrey Tan Gek Meng joined as consultant orthopedic surgeon in August 2026.
Changes in key executive roles may impact company operations and strategy execution. - Reverse share split
The company effected a 1-for-12 reverse share split in June 2026 to satisfy Nasdaq's minimum bid price requirement, resulting in 1,582,111 ordinary shares outstanding as of June 30, 2026.
Reverse split reduces share count and increases per-share price; company regained compliance with Nasdaq listing rules. - Management fee arrangements
Management fee of S$4,900,000 incurred between Singapore holding company and subsidiary for both FY2026 and FY2025.
Related party transaction represents approximately 30% of revenue; consistent with prior year. - Bitcoin acquisition plan terminated
The company announced a potential Bitcoin acquisition plan in May 2025 but put it on hold indefinitely in July 2025 due to regulatory review uncertainty.
Company abandoned plans to diversify into digital assets; no current intention to restart.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow BMGL in real time
Get material earnings, filing, IR, and earnings-call alerts by email.